YOU QUESTION: "How is the (longs) TRUST LEVEL SO HIGH...?"
EASY ANSWER: SUCCESS and POSITIVE FACTS DO NOT LIE.!!!
Below...ALL FACTS!
October 2, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING REQUEST GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF COVID-19
September 15, 2020
LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100 PERCENT
August 26, 2020DR.
WILLIAM F. DEGRADO, A DISCOVERER OF BRILACIDIN, JOINS INNOVATION PHARMACEUTICALS AS SCIENTIFIC ADVISOR
August 24, 2020
COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY INDEX AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2 ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING
August 4, 2020
INNOVATION PHARMACEUTICALS AND U.S. REGIONAL BIOCONTAINMENT LABORATORY NEARING COMPLETION OF BRILACIDIN ANTI-SARS-COV-2 (COVID-19) IN VITRO TESTING
July 20, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS NOVEL CORONAVIRUS (COVID-19) BY ALMOST 90% AT THE LOWEST CONCENTRATION TESTED TO DATE IN A HUMAN LUNG CELL LINE
July 13, 2020
INNOVATION PHARMACEUTICALS – CLINICAL TRIAL TESTING OF BRILACIDIN AGAINST SARS-COV-2 (COVID-19) TARGETED TO COMMENCE Q4 2020
July 7, 2020
IN VITRO TESTING OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR COVID-19 SHOWS CONSISTENT ANTI-SARS-COV-2 EFFICACY; MANUFACTURING PREPARATION UNDERWAY FOR COVID-19 CLINICAL TRIAL
June 17, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) BY 97 PERCENT IN A HUMAN LUNG CELL LINE
June 11, 2020
INNOVATION PHARMACEUTICALS COLLABORATING WITH REGIONAL BIOCONTAINMENT LAB ON GRANT APPLICATION TO RESEARCH BRILACIDIN AS A PAN-CORONAVIRUS THERAPEUTIC
May 26, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC HEALTH RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) IN A HUMAN CELL LINE
May 19, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN REDUCES VIRAL TITER OF SARS-COV-2 (COVID-19) BY 75 PERCENT AFTER ONLY 1 HOUR OF PREINCUBATION IN IN VITRO STUDY AT BSL-3 FACILITY
May 5, 2020
INHIBITORY EFFECT OF INNOVATION PHARMACEUTICALS’ BRILACIDIN ON SARS-COV-2 (COVID-19) IN PRIMARY HUMAN IMMUNE CELLS TO BE STUDIED AT LEADING PUBLIC HEALTH RESEARCH INSTITUTE
April 27, 2020
INNOVATION PHARMACEUTICALS INFORMED NEXT PHASE OF BRILACIDIN CORONAVIRUS (COVID-19) TESTING TO BEGIN WEEK OF MAY 4
April 6, 2020
INNOVATION PHARMACEUTICALS IN DISCUSSIONS TO ADVANCE BRILACIDIN INTO HUMAN TRIALS AGAINST COVID-19
April 1, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA SUPPORTING BRILACIDIN’S DIRECT INHIBITION OF SARS-COV-2, THE NOVEL CORONAVIRUS RESPONSIBLE FOR COVID-19
March 17, 2020
INNOVATION PHARMACEUTICALS BRILACIDIN TO BE RESEARCHED AS POSSIBLE NOVEL CORONAVIRUS (COVID-19) VACCINE; BRILACIDIN NOW BEING TESTED AS DRUG AND VACCINE AT DIFFERENT INSTITUTIONS
AI
